Lack of effects of HER-2/neu on prognosis in colorectal cancer: A meta-analysis

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 14, 2014, Pages 5551-5556

  Han, Jun ^a   Meng, Qing Yang ^a   Liu, Xiao ^b   Xi, Qiu Lei ^a   Zhuang, Qiu Lin ^a   Wu, Guo Hao ^a  

^a FUDAN UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Colorectal cancer; Human epidermal growth factor receptor 2; Meta analysis; Overall survival; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; TUMOR MARKER;

ASIAN CONTINENTAL ANCESTRY GROUP; BIOSYNTHESIS; CAUCASIAN; COLORECTAL TUMOR; GENETICS; HUMAN; META ANALYSIS; METABOLISM; MORTALITY; PROGNOSIS;

ASIAN CONTINENTAL ANCESTRY GROUP; COLORECTAL NEOPLASMS; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; PROGNOSIS; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 84905975389     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.14.5551     Document Type: Article

References (52)

1. Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50, 1088-101.
2. Conradi LC, Styczen H, Sprenger T, et al (2013). Frequency of HER-2 positivity in rectal cancer and prognosis. Am J Surg Pathol, 37, 522-31.
3. De Graeff P, Crijns AP, de Jong S, et al (2009). Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis. Br J Cancer, 101, 149-59.
4. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
5. Egger M, Davey SG., Schneider M, Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34.
6. Essapen S, Thomas H, Green M, et al (2004). The expression and prognostic significance of HER-2 in colorectal cancer and its relationship with clinicopathological parameters. Int J Oncol, 24, 241-8.
7. Harris CA, Ward RL, Dobbins TA, Drew AK, Pearson S (2011). The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis. Ann Oncol, 22, 1308-17.
8. Higgins JP, Thompson SG. (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58.
9. Huang Y, Li W, Chu D, et al (2011). Overexpression of matrix metalloproteinase-21 is associated with poor overall survival of patients with colorectal cancer. J Gastrointest Surg, 15, 1188-94.
10. Iivanainen E, Nelimarkka L, Elenius V, et al (2003). Angiopoietin-regulated recruitment of vascular smooth muscle cells by endothelial-derived heparin binding EGF-like growth factor. FASEB J, 17, 1609-21.
11. Izumi Y, Xu L, di TE, Fukumura D, Jain RK (2002). Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature, 416, 279-80.
12. JemalA, Siegel R, Xu J, Ward E (2010). Cancer statistics, 2010. CA Cancer J Clin, 60, 277-300.
13. Jesus EC, Matos D, Artigiani R, et al (2005). Assessment of staging, prognosis and mortality of colorectal cancer by tumor markers: receptor erbB-2 and cadherins. Acta Cir Bras, 20, 422-27.
14. Kapitanovic S, Radosevic S, Kapitanovic M, et al (1997). The expression of p185 (HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology, 112, 1103-13.
15. Kara O, Duman BB, Kara B, et al (2012). Analysis of PTEN, VEGF, HER2 and P53 status in determining colorectal cancer benefit from bevacizumab therapy. Asian Pac J Cancer Prev, 13, 6397-401.
16. Kavanagh DO, Chambers G., O'Grady L, et al (2009). Is overexpression of HER-2 a predictor of prognosis in colorectal cancer. BMC Cancer, 9, 1.
17. Kay EW, Mulcahy H, Walsh CB, Leader M, O'Donoghue D (1994). Cytoplasmic c-erbB-2 protein expression correlates with survival in Dukes' B colorectal carcinoma. Histopathology, 25, 455-61.
18. Knosel T, Yu Y, Stein U, et al (2002). Overexpression of c-erbB-2 protein correlates with chromosomal gain at the c-erbB-2 locus and patient survival in advanced colorectal carcinomas. Clin Exp Metastasis, 19, 401-7.
19. Kountourakis P, Pavlakis K, Psyrri A, et al (2006). Clinicopathologic significance of EGFR and Her-2/neu in colorectal adenocarcinomas. Cancer J, 12, 229-36.
20. Kovacevic D, Sonicki Z, Kusic Z, et al (2007). Preoperative serum levels of c-erbB-2 do not seem to be useful in management of patients with rectal cancer. Int J Colorectal Dis, 22, 827-31.
21. Kruszewski WJ, Rzepko R, Ciesielski M, et al (2010). Expression of HER2 in colorectal cancer does not correlate with prognosis. Dis Markers, 29, 207-12.
22. Lazaris AC, Theodoropoulos G E, Anastassopoulos P, et al (1995). Prognostic significance of p53 and c-erbB-2 immunohistochemical evaluation in colorectal adenocarcinoma. Histol Histopathol, 10, 661-8.
23. Li Q, Wang D, Li J, Chen P (2011). Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas. BMC Cancer, 11, 277.
24. Li YG., Geng X (2010). A meta-analysis on the association of HER-2 overexpression with prognosis in human osteosarcoma. Eur J Cancer Care, 19, 313-6.
25. Lim SW, Kim HR, Kim HY, et al (2013). Over-expression of Her- 2 in colorectal cancer tissue, but not in serum, constitutes an independent worse prognostic factor. Cell Oncol, 36, 311-21.
26. McKay JA, Loane JF, Ross VG, et al (2002). c-erbB-2 is not a major factor in the development of colorectal cancer. Br J Cancer, 86, 568-73.
27. McShane LM, Altman DG, Sauerbrei W, et al (2005). REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer, 93, 387-91.
28. Meert AP, Martin B, Paesmans M, et al (2003). The role of HER- 2/neu expression on the survival of patients with lung cancer: a systematic review of the literature. Br J Cancer, 89, 959-65.
29. Mehrkhani F, Nasiri S, Donboli K, Meysamie A, Hedayat A (2009). Prognostic factors in survival of colorectal cancer patients after surgery. Colorectal Dis, 11, 157-61.
30. Molaei M, Pejhan S, Nayer BN, et al (2009). Human epidermal growth factor receptor-2 family in colorectal adenocarcinoma: correlation with survival and clinicopathological findings. Eur J Gastroenterol Hepatol, 21, 289-93.
31. Neto AS, Tobias-Machado M, Wroclawski ML, et al (2010). Her- 2/neu expression in prostate adenocarcinoma: a systematic review and meta-analysis. J Urol, 184, 842-50.
32. Ochs AM, Wong L, Kakani V, et al (2004). Expression of vascular endothelial growth factor and HER2/neu in stage II colon cancer and correlation with survival. Clin Colorectal Cancer, 4, 262-7.
33. Oldenhuis CN, Oosting SF, Gietema JA, de Vries EG (2008). Prognostic versus predictive value of biomarkers in oncology. Eur J Cancer, 44, 946-53.
34. Osako T, Miyahara M, Uchino S, et al (1998). Immunohistochemical study of c-erbB-2 protein in colorectal cancer and the correlation with patient survival. Oncology, 55, 548-55.
35. Pappas A, Lagoudianakis E, Seretis C, et al (2013). Clinical role of HER-2/neu expression in colorectal cancer. J BUON, 18, 98-104.
36. Park DI, Kang MS, Oh SJ, et al (2007). HER-2/neu overexpression is an independent prognostic factor in colorectal cancer. Int J Colorectal Dis, 22, 491-7.
37. Park YJ, Park KJ, et al (1999). Prognostic factors in 2230 Korean colorectal cancer patients: analysis of consecutively operated cases. World J Surg, 23, 721-6.
38. Parmar MK, Torri V, Stewart L (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 17, 2815-34.
39. Ren H, Li J, Liu JJ, Guo HL, Jiang T (2012). Anti-HER-2 anti-CD3 bi-specific antibodies inhibit growth of HCT-116 colorectal carcinoma cells in vitro and in vivo. Asian Pac J Cancer Prev, 13, 2795-8.
40. Rossi HA, Liu Q, Banner B, et al (2002). The prognostic value of invariant chain (Ii) and Her-2/neu expression in curatively resected colorectal cancer. Cancer J, 8, 268-75
41. Sanz-Casla MT, Vidaurreta M, Maestro ML, et al (2004). Prognostic significance of the p185 protein in colorectal cancer. Rev Esp Enferm Dig, 96, 102-9.
42. Schuell B, Gruenberger T, Scheithauer W, Ch Z, Wrba F (2006). HER 2/neu protein expression in colorectal cancer. BMC Cancer, 6, 123.
43. Seidal T, Balaton AJ, Battifora H (2001). Interpretation and quantification of immunostains. Am J Surg Pathol, 25, 1204-7.
44. Sun XF, Carstensen JM, Nordenskjold B (1995). Expression of c-erbB-2 and p53 in colorectal adenocarcinoma. Anal Cell Pathol, 8, 203-11.
45. Sun XF, Carstensen JM, Stal O, Zhang H, Nordenskjold B (1995). c-erbB-2 oncoprotein in relation to DNA ploidy and prognosis in colorectal adenocarcinoma. APMIS, 103, 309-15.
46. Sung JJ, Lau JY, Goh KL, Leung WK (2005). Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol, 6, 871-6.
47. Thompson SG., Higgins JP (2002). How should meta-regression analyses be undertaken and interpreted. Stat Med, 21, 1559-73.
48. Tsigris C, Karayiannakis AJ, Zbar A, et al (2002). Clinical significance of serum and urinary c-erbB-2 levels in colorectal cancer. Cancer Lett, 184, 215-22.
49. Uner A, Ebinc FA, Akyurek N, et al (2005). Vascular endothelial growth factor, c-erbB-2 and c-erbB-3 expression in colorectal adenoma and adenocarcinoma. Exp Oncol, 27, 225-8.
50. Wang S, Zheng G., Chen L, Xiong B, (2011). Effect of HER-2/ neu over-expression on prognosis in gastric cancer: a meta-analysis. Asian Pac J Cancer Prev, 12, 1417-23.
51. Wingens M, Walma T, van Ingen H, et al (2003). Structural analysis of an epidermal growth factor/transforming growth factor-alpha chimera with unique ErbB binding specificity. J Biol Chem, 278, 39114-23.
52. Xiong Y, Fang Z, Zhang C, et al (2011). Copy number increase of HER-2 in colorectal cancers. Oncol Lett, 2, 331-5.